# 📄 What This Document Is This is a formal update (an "SC TO-T/A" filing) about a **tender offer**—a type of direct buyout offer. Gilead Sciences is trying to buy all the shares of a smaller company called Arcellx. This specific filing announces that Gilead is **extending the deadline** for Arcell

Read summaryView on SEC EDGAR

SEC filings

All filings →

1 recent filing shown in the timeline above. View all SEC filings →

Insider trades

All insider trades →

ACLX has no reported insider trades in the last 90 days.

Institutional holders

All holders →

As of 2025-12-31 · prior 2025-09-30

FMR LLC$232.4M

3,563,728 sh-38.1%

RA CAPITAL MANAGEMENT, L.P.$82.6M

1,267,156 sh-58.3%

GILEAD SCIENCES, INC.$438.2M

6,720,803 sh0.0%

PERCEPTIVE ADVISORS LLC$95.6M

1,466,071 sh-40.6%

Vestal Point Capital, LP$190.7M

2,925,000 sh+134.0%

AJU IB Investment Co., Ltd.$14.6M

223,486 sh-78.7%

VANGUARD GROUP INC$266.1M

4,081,519 sh+4.5%

NEA Management Company, LLC$198.6M

3,045,262 sh0.0%

People at ACLX

Quarterly financials

Full financials →

Revenue trend

03/25

$8.1M

NI -$62.3M

06/25

$7.6M

NI -$52.8M

09/25

$4.9M

NI -$55.8M

RevenueNI = Net Income

EPS trend (diluted)

Latest: $-0.99

Prior: $-0.94

Revenue sparkline